SCHEDULE: Belite Bio: Yu-Hsin Lin Reports 3.1% Stake

Yu-Hsin Lin, CEO and Chairman of Belite Bio, Inc., has filed a Schedule 13G, reporting beneficial ownership of 3.1% of the company's ordinary shares as of March 31, 2026.

Summary

• Yu-Hsin Lin, CEO and Chairman of Belite Bio, Inc., has filed an amendment to Schedule 13G, reporting beneficial ownership of 1,253,935 ordinary shares as of March 31, 2026.
• This represents 3.1% of the company's ordinary shares outstanding.
• The filing details that 353,083 shares are directly held, 900,852 shares are held through vested options and RSUs, and 1,474,527 shares are indirectly held through Lin BioScience, Inc.
• Yu-Hsin Lin disclaims investment and disposition power over the indirectly held shares.
• The percentage calculation includes shares underlying options and RSUs that will vest within 60 days of March 31, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it is a routine disclosure of beneficial ownership and does not provide new financial performance data or strategic updates.

Positives

• Yu-Hsin Lin, a key executive, has disclosed his beneficial ownership, providing transparency to shareholders.
• The disclosed stake of 3.1% indicates a significant personal investment by the CEO and Chairman in the company.

Negatives

• Yu-Hsin Lin disclaims investment and disposition power over a substantial portion of indirectly held shares (1,474,527 shares), which may limit his direct influence over these holdings.

Risks

• The disclaimer of control over indirectly held shares could raise questions about the ultimate beneficial ownership and control structure.
• Potential future dilution could impact the percentage of ownership if more shares are issued.

Future Outlook

The filing itself does not contain forward-looking statements or guidance regarding future performance. It is a disclosure of beneficial ownership.

Management Comments

• Yu-Hsin Lin, Chief Executive Officer and Chairman, certified the accuracy of the filing.
• Yu-Hsin Lin disclaims investment and disposition power of the 1,474,527 Ordinary Shares indirectly held by Yu-Hsin Lin through Lin BioScience, Inc. and Lin Bioscience International Ltd.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are standard disclosures for significant beneficial ownership by institutional investors or individuals. This filing provides insight into the holdings of a key executive at Belite Bio, Inc., a biotechnology company.

Stakeholder Impact

• Shareholders gain transparency into the beneficial ownership of a key executive, potentially influencing perceptions of management alignment with shareholder interests.
• The disclaimer of control over a portion of shares may lead to scrutiny regarding the effective control and decision-making power of the CEO.

Next Steps

• Continued monitoring of future SEC filings for any changes in beneficial ownership or company disclosures.

Key Dates

Keywords

Belite Bio, Schedule 13G, Yu-Hsin Lin, Beneficial Ownership, Ordinary Shares, SEC Filing, Lin BioScience, Stock Options, RSUs